Analysts See $-0.26 EPS for Trevena, Inc. (TRVN)

February 23, 2018 - By Michael Collier

 Analysts See $ 0.26 EPS for Trevena, Inc. (TRVN)

Analysts expect Trevena, Inc. (NASDAQ:TRVN) to report $-0.26 EPS on March, 14.They anticipate $0.41 EPS change or 61.19 % from last quarter’s $-0.67 EPS. After having $-0.27 EPS previously, Trevena, Inc.’s analysts see -3.70 % EPS growth. The stock decreased 0.61% or $0.01 during the last trading session, reaching $1.63. About 370,795 shares traded. Trevena, Inc. (NASDAQ:TRVN) has declined 52.53% since February 23, 2017 and is downtrending. It has underperformed by 69.23% the S&P500.

Trevena, Inc. (NASDAQ:TRVN) Ratings Coverage

Among 14 analysts covering Trevena Inc (NASDAQ:TRVN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Trevena Inc had 23 analyst reports since August 3, 2015 according to SRatingsIntel. Roth Capital maintained Trevena, Inc. (NASDAQ:TRVN) on Friday, July 21 with “Buy” rating. The rating was maintained by Cowen & Co with “Outperform” on Tuesday, September 1. WallachBeth Capital initiated the stock with “Buy” rating in Wednesday, March 2 report. The firm has “Buy” rating given on Monday, August 3 by Brean Capital. Oppenheimer maintained it with “Buy” rating and $800 target in Thursday, August 3 report. The stock of Trevena, Inc. (NASDAQ:TRVN) has “Buy” rating given on Thursday, February 23 by H.C. Wainwright. The stock has “Buy” rating by Needham on Thursday, August 3. The stock of Trevena, Inc. (NASDAQ:TRVN) earned “Buy” rating by Cowen & Co on Thursday, August 3. As per Tuesday, March 29, the company rating was initiated by FBR Capital. The stock has “Buy” rating by H.C. Wainwright on Monday, January 9.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $101.55 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

More news for Trevena, Inc. (NASDAQ:TRVN) were recently published by:, which released: “Quotidian Technical Highlights on Selected Biotech Stocks — Tesaro, Trevena …” on February 21, 2018.‘s article titled: “Trevena Promotes Carrie Bourdow to Executive Vice President and Chief …” and published on February 02, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.